The Hyaluronidase Activity ELISA is a quantitative immunoassay designed for in vitro measurement of hyaluronidase activity in biological samples. Sample Type: Biological samples (human sera, plasma, and urine samples) and purified Hyaluronidase. Sample Volume: 12 µL/ duplicates Assay Incubation Time: 2 hours and 30 min + enzyme reaction time Assay Range: 0.078-5
µg HA
Product Background
The Hyaluronidase Activity ELISA is a quantitative immunoassay designed for the in vitro measurement of hyaluronidase activity in biological samples. Hyaluronidase reactions are performed in a 96-well plate pre-coated with HA substrate. The activity of the hyaluronidase is determined by comparing HA substrate levels post reaction to a standard curve of pre-coated HA substrate. The Hyaluronidase Activity ELISA has been validated with human sera, plasma, urine and purified hyaluronidase from bovine testes. The Hyaluronidase Activity ELISA provides a robust and simple method for researchers to measure hyaluronidase activity in biological samples. Hyaluronidases are a group of enzymes that degrade Hyaluronan (HA), a linear polysaccharide comprised of a repeating disaccharide of N-acetylglucosamine and D-glucuronic acid. HA is involved in many biological processes including structural support, cell migration and tissue turnover. Circulating HA levels correlate in several disorders such as liver disease and certain types of cancer. Hyaluronidases have become an important area of study due to their regulatory function in HA metabolism and their role in physiological processes such as fertilization and wound healing. Elevated expression levels of the gene encoding Hyaluronidase 1 have been found in atypical ductal hyperplastic tissues, suggesting the possibility that it may be a viable biomarker for identifying premalignant lesions that can develop into breast cancer. Research has also shown that hyaluronidases are involved in several pathological processes such as bacterial pathogenesis, the spreading of toxins/venoms and cancer progression, making hyaluronidases a potential pharmacological target.
Featured in Publications
1. Chang, S.-H., et al. (2017). Transforming growth factor-beta-mediated CD44/STAT3 signaling contributes to the development of atrial fibrosis and fibrillation. Basic Research in Cardiology 112(5): 58. 2. Margraf, A., et al. (2018). 6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice. Critical Care 22(1): 111. 3. De Robertis, M., et al. (2018). In Vivo Evaluation of a New Recombinant Hyaluronidase to Improve Gene Electro-Transfer Protocols for DNA-Based Drug Delivery against Cancer. Cancers 10(11): 405. Product Keywords: Hyaluronan, Hyaluronate, Liver Cirrhosis, Rheumatoid Arthritis, Osteoarthritis, Liver Fibrosis
Documents
Technical Data Sheet
